➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Baxter
Express Scripts
McKesson
Dow

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

GEMFIBROZIL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Gemfibrozil, and what generic alternatives are available?

Gemfibrozil is a drug marketed by Mylan, Purepac Pharm, Apotex, Aurobindo Pharma Ltd, Cadila, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Sun Pharm Inds Inc, Teva, Watson Labs, and Yaopharma Co Ltd. and is included in nineteen NDAs.

The generic ingredient in GEMFIBROZIL is gemfibrozil. Twenty-five suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.

US ANDA Litigation and Generic Entry Outlook for Gemfibrozil

A generic version of GEMFIBROZIL was approved as gemfibrozil by CHARTWELL MOLECULES on September 27th, 1993.

  Start Trial

Drug patent expirations by year for GEMFIBROZIL
Drug Prices for GEMFIBROZIL

See drug prices for GEMFIBROZIL

Drug Sales Revenue Trends for GEMFIBROZIL

See drug sales revenues for GEMFIBROZIL

Recent Clinical Trials for GEMFIBROZIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Seattle Genetics, Inc.Phase 1
CelgenePhase 1
Instituto Nacional de Salud Publica, MexicoPhase 3

See all GEMFIBROZIL clinical trials

Medical Subject Heading (MeSH) Categories for GEMFIBROZIL

US Patents and Regulatory Information for GEMFIBROZIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan GEMFIBROZIL gemfibrozil CAPSULE;ORAL 073466-001 Jan 25, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs GEMFIBROZIL gemfibrozil TABLET;ORAL 074442-001 Apr 28, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
Caribe Holdings GEMFIBROZIL gemfibrozil TABLET;ORAL 078012-001 Mar 26, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd GEMFIBROZIL gemfibrozil TABLET;ORAL 202726-001 Sep 16, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan GEMFIBROZIL gemfibrozil TABLET;ORAL 074452-001 Feb 16, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Colorcon
Boehringer Ingelheim
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.